{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:38:27Z","timestamp":1786365507421,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,10,15]],"date-time":"2013-10-15T00:00:00Z","timestamp":1381795200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s10620-013-2900-x","type":"journal-article","created":{"date-parts":[[2013,10,14]],"date-time":"2013-10-14T03:24:09Z","timestamp":1381721049000},"page":"383-389","source":"Crossref","is-referenced-by-count":46,"title":["Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H. pylori Infection"],"prefix":"10.1007","volume":"59","author":[{"name":"On behalf of the H. pylori Study Group of the Spanish Gastroenterology Association","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Gisbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Perez-Aisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Molina-Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Modolell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Castro-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Sacrist\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cosme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Harb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gonzalez-Barcenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fernandez-Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Algaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G.","family":"McNicholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,15]]},"reference":[{"key":"2900_CR1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1365-2036.2002.01276.x","volume":"16","author":"JP Gisbert","year":"2002","unstructured":"Gisbert JP, Pajares JM. Review article: Helicobacter pylori \u201crescue\u201d regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16:1047\u20131057.","journal-title":"Aliment Pharmacol Ther"},{"key":"2900_CR2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","volume":"61","author":"P Malfertheiner","year":"2012","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, et al. Management of Helicobacter pylori infection\u2014the Maastricht IV\/florence consensus report. Gut. 2012;61:646\u2013664.","journal-title":"Gut"},{"key":"2900_CR3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MCG.0b013e318254ebdd","volume":"47","author":"JP Gisbert","year":"2013","unstructured":"Gisbert JP, Perez-Aisa A, Bermejo F, et al. Second-line therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol. 2013;47:130\u2013135.","journal-title":"J Clin Gastroenterol"},{"key":"2900_CR4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1523-5378.2005.00324.x","volume":"10","author":"JP Gisbert","year":"2005","unstructured":"Gisbert JP, Pajares JM. Helicobacter pylori \u201crescue\u201d therapy after failure of two eradication treatments. Helicobacter. 2005;10:363\u2013372.","journal-title":"Helicobacter"},{"key":"2900_CR5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1590-8658(03)00081-1","volume":"35","author":"A Zullo","year":"2003","unstructured":"Zullo A, Hassan C, Lorenzetti R, Winn S, Morini S. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig Liver Dis. 2003;35:357\u2013361.","journal-title":"Dig Liver Dis"},{"key":"2900_CR6","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.2169\/internalmedicine.50.5135","volume":"50","author":"JP Gisbert","year":"2011","unstructured":"Gisbert JP. Is culture necessary before first-line treatment for Helicobacter pylori infection? Intern Med. 2011;50:2717.","journal-title":"Intern Med"},{"key":"2900_CR7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1083-4389.2004.00195.x","volume":"9","author":"JP Gisbert","year":"2004","unstructured":"Gisbert JP, Badia X, Roset M, Pajares JM. The TETRA study: a prospective evaluation of Helicobacter pylori \u2018test-and-treat\u2019 strategy on 736 patients in clinical practice. Helicobacter. 2004;9:28\u201338.","journal-title":"Helicobacter"},{"key":"2900_CR8","doi-asserted-by":"crossref","unstructured":"Gisbert JP. Rescue therapy for Helicobacter pylori infection 2012. Gastroenterol Res Pract. 2012;2012:974594.","DOI":"10.1155\/2012\/974594"},{"key":"2900_CR9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.2006.02737.x","volume":"23","author":"JP Gisbert","year":"2006","unstructured":"Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23:35\u201344.","journal-title":"Aliment Pharmacol Ther"},{"key":"2900_CR10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1572-0241.2006.00637.x","volume":"101","author":"RJ Saad","year":"2006","unstructured":"Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006;101:488\u2013496.","journal-title":"Am J Gastroenterol"},{"key":"2900_CR11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00508-010-1404-3","volume":"122","author":"Y Li","year":"2010","unstructured":"Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr. 2010;122:413\u2013422.","journal-title":"Wien Klin Wochenschr"},{"key":"2900_CR12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1046\/j.1365-2036.2000.00833.x","volume":"14","author":"F Gomollon","year":"2000","unstructured":"Gomollon F, Sicilia B, Ducons JA, Sierra E, Revillo MJ, Ferrero M. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther. 2000;14:1335\u20131338.","journal-title":"Aliment Pharmacol Ther"},{"key":"2900_CR13","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0210-5705(02)70283-5","volume":"25","author":"R Vicente","year":"2002","unstructured":"Vicente R, Sicilia B, Gallego S, Revillo MJ, Ducons J, Gomollon F. Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures: a prospective culture-guided study. Gastroenterol Hepatol. 2002;25:438\u2013442.","journal-title":"Gastroenterol Hepatol"},{"key":"2900_CR14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1365-2036.2004.01910.x","volume":"19","author":"G Cammarota","year":"2004","unstructured":"Cammarota G, Martino A, Pirozzi G, et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther. 2004;19:789\u2013795.","journal-title":"Aliment Pharmacol Ther"},{"key":"2900_CR15","doi-asserted-by":"crossref","unstructured":"Baena Diez JM, Lopez Mompo C, Rams Rams F, Garcia Lareo M, Hernandez Ibanez MR, Teruel Gila J. Eficacia de una terapia secuencial en la erradicaci\u00f3n de Helicobacter pylori: cu\u00e1druple terapia con omeprazol, metronidazol, tetraciclina y bismuto tras el fracaso de la combinaci\u00f3n de omeprazol, claritromicina y amoxicilina. Med Clin (Barc). 2000;115:617\u2013619.","DOI":"10.1016\/S0025-7753(00)71640-X"},{"key":"2900_CR16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1542-3565(04)00458-6","volume":"2","author":"C Bilardi","year":"2004","unstructured":"Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol. 2004;2:997\u20131002.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2900_CR17","first-page":"131","volume":"47","author":"RS Choung","year":"2006","unstructured":"Choung RS, Lee SW, Jung SW, et al. Comparison of the effectiveness of quadruple salvage regimen for Helicobacter pylori infection according to the duration of treatment. Korean J Gastroenterol. 2006;47:131\u2013135.","journal-title":"Korean J Gastroenterol"},{"key":"2900_CR18","first-page":"1293","volume":"54","author":"SJ Chung","year":"2007","unstructured":"Chung SJ, Lee DH, Kim N, et al. Eradication rates of Helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease. Hepatogastroenterology. 2007;54:1293\u20131296.","journal-title":"Hepatogastroenterology"},{"key":"2900_CR19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1523-5378.2011.00844.x","volume":"16","author":"JW Chung","year":"2011","unstructured":"Chung JW, Lee JH, Jung HY, et al. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter. 2011;16:289\u2013294.","journal-title":"Helicobacter"},{"key":"2900_CR20","first-page":"83","volume":"21","author":"IR Elizalde","year":"1998","unstructured":"Elizalde IR, Borda F, Jara C, Mart\u00ednez A, Rodr\u00edguez C, Jim\u00e9nez J. Eficacia de dos tratamientos consecutivos en la erradicaci\u00f3n de Helicobacter pylori. Anal Sis San Navarra. 1998;21:83\u201388.","journal-title":"Anal Sis San Navarra"},{"key":"2900_CR21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/003655200750024119","volume":"35","author":"A Gasbarrini","year":"2000","unstructured":"Gasbarrini A, Ojetti V, Pitocco D, et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol. 2000;35:260\u2013263.","journal-title":"Scand J Gastroenterol"},{"key":"2900_CR22","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1046\/j.1365-2036.1999.00615.x","volume":"13","author":"JP Gisbert","year":"1999","unstructured":"Gisbert JP, Gisbert JL, Marcos S, Gravalos RG, Carpio D, Pajares JM. Seven-day \u2018rescue\u2019 therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther. 1999;13:1311\u20131316.","journal-title":"Aliment Pharmacol Ther"},{"key":"2900_CR23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/00042737-199909000-00018","volume":"11","author":"JP Gisbert","year":"1999","unstructured":"Gisbert JP, Boixeda D, Bermejo F, et al. Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol. 1999;11:1049\u20131054.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2900_CR24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1523-5378.1999.99307.x","volume":"4","author":"F Gomollon","year":"1999","unstructured":"Gomollon F, Ducons JA, Ferrero M, et al. Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. Helicobacter. 1999;4:222\u2013225.","journal-title":"Helicobacter"},{"key":"2900_CR25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-2036.1999.00504.x","volume":"13","author":"JM Lee","year":"1999","unstructured":"Lee JM, Breslin NP, Hyde DK, Buckley MJ, O\u2019Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther. 1999;13:489\u2013496.","journal-title":"Aliment Pharmacol Ther"},{"key":"2900_CR26","first-page":"94","volume":"46","author":"JH Lee","year":"2005","unstructured":"Lee JH, Cheon JH, Park MJ, et al. The trend of eradication rates of second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years. Korean J Gastroenterol. 2005;46:94\u201398.","journal-title":"Korean J Gastroenterol"},{"key":"2900_CR27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1523-5378.2009.00735.x","volume":"15","author":"BH Lee","year":"2010","unstructured":"Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter. 2010;15:38\u201345.","journal-title":"Helicobacter"},{"key":"2900_CR28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1523-5378.2005.00288.x","volume":"10","author":"D Marko","year":"2005","unstructured":"Marko D, Calvet X, Ducons J, Guardiola J, Tito L, Bory F. Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis. Helicobacter. 2005;10:22\u201332.","journal-title":"Helicobacter"},{"key":"2900_CR29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2036.2000.00761.x","volume":"14","author":"S Michopoulos","year":"2000","unstructured":"Michopoulos S, Tsibouris P, Bouzakis H, et al. Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens. Aliment Pharmacol Ther. 2000;14:737\u2013744.","journal-title":"Aliment Pharmacol Ther"},{"key":"2900_CR30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-230X-7-31","volume":"7","author":"JM Navarro-Jarabo","year":"2007","unstructured":"Navarro-Jarabo JM, Fernandez N, Sousa FL, et al. Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection. BMC Gastroenterol. 2007;7:31.","journal-title":"BMC Gastroenterol"},{"key":"2900_CR31","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1046\/j.1365-2036.2003.01676.x","volume":"18","author":"EC Nista","year":"2003","unstructured":"Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther. 2003;18:627\u2013633.","journal-title":"Aliment Pharmacol Ther"},{"key":"2900_CR32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1523-5378.2003.t01-2-00159.x","volume":"8","author":"P Orsi","year":"2003","unstructured":"Orsi P, Pinazzi O, Aragona G, Di Mario F. Rabeprazole\/Levofloxacin based triple therapy as a salvatage treatment after failure of H. pylori eradication with standard regimens. Helicobacter. 2003;8:339\u2013493.","journal-title":"Helicobacter"},{"key":"2900_CR33","first-page":"58","volume":"96","author":"F Perri","year":"2001","unstructured":"Perri F, Festa V, Clemente R, et al. Randomized study of two \u201crescue\u201d therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol. 2001;96:58\u201362.","journal-title":"Am J Gastroenterol"},{"key":"2900_CR34","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1046\/j.1365-2036.2003.01755.x","volume":"18","author":"F Perri","year":"2003","unstructured":"Perri F, Festa V, Merla A, Barberani F, Pilotto A, Andriulli A. Randomized study of different \u2018second-line\u2019 therapies for Helicobacter pylori infection after failure of the standard \u2018Maastricht triple therapy\u2019. Aliment Pharmacol Ther. 2003;18:815\u2013820.","journal-title":"Aliment Pharmacol Ther"},{"key":"2900_CR35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0025-7753(00)71649-6","volume":"115","author":"B Sicilia","year":"2000","unstructured":"Sicilia B, Sierra E, Lago A, Villar M, Garcia S, Gomollon F. High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy. Med Clin (Barc). 2000;115:641\u2013643.","journal-title":"Med Clin (Barc)"},{"key":"2900_CR36","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00535-008-2187-4","volume":"43","author":"Y Usta","year":"2008","unstructured":"Usta Y, Saltik-Temizel IN, Demir H, et al. Comparison of short- and long-term treatment protocols and the results of second-line quadruple therapy in children with Helicobacter pylori infection. J Gastroenterol. 2008;43:429\u2013433.","journal-title":"J Gastroenterol"},{"key":"2900_CR37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1440-1746.2007.05272.x","volume":"23","author":"A Uygun","year":"2008","unstructured":"Uygun A, Ozel AM, Yildiz O, et al. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy. J Gastroenterol Hepatol. 2008;23:42\u201345.","journal-title":"J Gastroenterol Hepatol"},{"key":"2900_CR38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2036.2003.01459.x","volume":"17","author":"WM Wong","year":"2003","unstructured":"Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther. 2003;17:553\u2013560.","journal-title":"Aliment Pharmacol Ther"},{"key":"2900_CR39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-2362.2006.01725.x","volume":"36","author":"DC Wu","year":"2006","unstructured":"Wu DC, Hsu PI, Chen A, et al. Randomized comparison of two rescue therapies for Helicobacter pylori infection. Eur J Clin Invest. 2006;36:803\u2013809.","journal-title":"Eur J Clin Invest"},{"key":"2900_CR40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/MD.0b013e31821c9d1c","volume":"90","author":"DC Wu","year":"2011","unstructured":"Wu DC, Hsu PI, Tseng HH, et al. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies. Medicine (Baltimore). 2011;90:180\u2013185.","journal-title":"Medicine (Baltimore)"},{"key":"2900_CR41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","volume":"62","author":"F Megraud","year":"2013","unstructured":"Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34\u201342.","journal-title":"Gut"},{"key":"2900_CR42","first-page":"236","volume":"34","author":"E P\u00e9rez-Trallero","year":"2011","unstructured":"P\u00e9rez-Trallero E, Ram\u00edrez-L\u00e1zaro MJ, Villar H, et al. Resistencia de Helicobacter pylori a diversos antibi\u00f3ticos: un estudio multic\u00e9ntrico espa\u00f1ol. Gastroenterol Hepatol. 2011;34:236.","journal-title":"Gastroenterol Hepatol"},{"key":"2900_CR43","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2036.2012.05053.x","volume":"35","author":"JP Gisbert","year":"2012","unstructured":"Gisbert JP, Castro-Fernandez M, Perez-Aisa A, et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther. 2012;35:941\u2013947.","journal-title":"Aliment Pharmacol Ther"},{"key":"2900_CR44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","volume":"35","author":"JP Gisbert","year":"2012","unstructured":"Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209\u2013221.","journal-title":"Aliment Pharmacol Ther"},{"key":"2900_CR45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ajg.2008.87","volume":"104","author":"T Rokkas","year":"2009","unstructured":"Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol. 2009;104:21\u201325.","journal-title":"Am J Gastroenterol"},{"key":"2900_CR46","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2036.2007.03573.x","volume":"27","author":"JP Gisbert","year":"2008","unstructured":"Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther. 2008;27:346\u2013354.","journal-title":"Aliment Pharmacol Ther"},{"key":"2900_CR47","first-page":"1993","volume":"89","author":"WA Boer de","year":"1994","unstructured":"de Boer WA, Driessen WM, Potters VP, Tytgat GN. Randomized study comparing 1 with 2\u00a0weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol. 1994;89:1993\u20131997.","journal-title":"Am J Gastroenterol"},{"key":"2900_CR48","first-page":"136","volume":"44","author":"SC Park","year":"2004","unstructured":"Park SC, Chun HJ, Jung SW, et al. Efficacy of 14\u00a0day OBMT therapy as a second-line treatment for Helicobacter pylori infection. Korean J Gastroenterol. 2004;44:136\u2013141.","journal-title":"Korean J Gastroenterol"},{"key":"2900_CR49","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1572-0241.2002.05600.x","volume":"97","author":"MP Dore","year":"2002","unstructured":"Dore MP, Graham DY, Mele R, et al. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol. 2002;97:857\u2013860.","journal-title":"Am J Gastroenterol"},{"key":"2900_CR50","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1523-5378.2003.00150.x","volume":"8","author":"MP Dore","year":"2003","unstructured":"Dore MP, Marras L, Maragkoudakis E, et al. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter. 2003;8:307\u2013309.","journal-title":"Helicobacter"},{"key":"2900_CR51","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","volume":"377","author":"P Malfertheiner","year":"2011","unstructured":"Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377:905\u2013913.","journal-title":"Lancet"},{"key":"2900_CR52","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrgastro.2011.84","volume":"8","author":"JP Gisbert","year":"2011","unstructured":"Gisbert JP. Helicobacter pylori eradication: a new, single-capsule bismuth-containing quadruple therapy. Nat Rev Gastroenterol Hepatol. 2011;8:307\u2013309.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2900_CR53","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1365-2036.2003.01566.x","volume":"17","author":"E Gene","year":"2003","unstructured":"Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther. 2003;17:1137\u20131143.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-013-2900-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-013-2900-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-013-2900-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T15:44:08Z","timestamp":1559231048000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-013-2900-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,15]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["2900"],"URL":"https:\/\/doi.org\/10.1007\/s10620-013-2900-x","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,15]]}}}